NCT04347616View on ClinicalTrials.gov

Natural Killer-cell Therapy for Acute Myeloid Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, Relapsed, Adult
Interventions
BIOLOGICAL

UCB-NK cells

Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood

DRUG

IL-2

In vivo cytokine support

Trial Locations (1)

Unknown

RECRUITING

Radboud University Medical Center, Nijmegen

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

lead

Radboud University Medical Center

OTHER